David Rolfe Bristol Myers Squibb CO Transaction History

Wedgewood Partners Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $85,600 - $101,362	-1,250 Reduced 23.04%	4,175 $300,000
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $65 - $38,420	-500 Reduced 8.44%	5,425 $385,000
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $72,620 - $79,980	-1,000 Reduced 14.44%	5,925 $456,000
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $138,330 - $165,870	2,250 Added 48.13%	6,925 $505,000
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $33,518 - $39,075	-625 Reduced 11.79%	4,675 $291,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $19,230 - $22,525	-325 Reduced 5.78%	5,300 $313,000
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $4.35 Million - $4.73 Million	-70,210 Reduced 92.58%	5,625 $375,000
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $20.1 Million - $22.6 Million	-338,222 Reduced 81.68%	75,835 $4.79 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $1.46 Million - $1.65 Million	-25,262 Reduced 5.75%	414,057 $25.7 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $3.76 Million - $4.17 Million	65,538 Added 17.53%	439,319 $26.5 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $6.28 Million - $7.34 Million	114,601 Added 44.22%	373,781 $22 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $6.14 Million - $8.92 Million	-132,262 Reduced 33.79%	259,180 $14.4 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $19.3 Million - $25.1 Million	391,442 New	391,442 $25.1 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Wedgewood Partners Inc, based on Form 13F filings with the SEC.

Stay updated on Wedgewood Partners Inc and David Rolfe with notifications on news.